יחס שווי פעילות לרווח לפני ריבית, מסים ופחת Cyclo Therapeutics, Inc (CYTH)

The EV/EBITDA valuation chart allows for an assessment of Cyclo Therapeutics (CYTH), whose advantages are based on exclusive rights to Trappsol Cyclo for the treatment of Niemann-Pick disease. The current metric stands at . The business relies on US laboratories and innovative drug development methods. FDA breakthrough therapy status strengthens the company's position in a narrow niche where patients have virtually no treatment alternatives.

This indicator compares the total enterprise value, including net debt, with its operating profit before taxes. By analyzing the EV/EBITDA multiple on a time chart, an investor determines the market overvaluation of assets relative to their ability to generate cash flow. For Cyclo Therapeutics (CYTH), this metric is extremely sensitive, as the lack of pricing power during the clinical trial stage makes future capitalization dependent solely on FDA approval.